Prentiss Smith & Co’s Sarepta Therapeutics SRPT Stock Holding History

Prentiss Smith & Co’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-722	Closed	-$117K	–	204
2018 Q3	$117K	Hold	722	–	–	0.07%	79
2018 Q2	$95K	Sell	722 -3,166	-81%	-$299K	0.06%	87
2018 Q1	$288K	Buy	3,888 +312	+9%	+$20.8K	0.15%	67
2017 Q4	$199K	Sell	3,576 -312	-8%	-$16.5K	0.1%	72
2017 Q3	$176K	Buy	3,888 +312	+9%	+$12.5K	0.1%	65
2017 Q2	$121K	Buy	3,576 +3,166	+772%	+$103K	0.06%	83
2017 Q1	$12K	Hold	410	–	–	0.01%	186
2016 Q4	$11K	Hold	410	–	–	0.01%	198
2016 Q3	$25K	Hold	410	–	–	0.01%	161
2016 Q2	$8K	Hold	410	–	–	﹤0.01%	223
2016 Q1	$8K	Buy	+410	New	+$7.16K	﹤0.01%	248

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Prentiss Smith & Co's SRPT Position: Q4 2018 in Review

Prentiss Smith & Co sold out of Sarepta Therapeutics (SRPT) in Q4 2018, closing a stake of 722 shares — an estimated $117K sold.

Prentiss Smith & Co first reported a position in SRPT in Q1 2016 and held it in 11 quarters. The position peaked at $288K in Q1 2018. 336 funds tracked by Wall St. Rank hold SRPT as of Q4 2018.

Prentiss Smith & Co reported no remaining Sarepta Therapeutics position as of Q4 2018 after selling out during the quarter.
Prentiss Smith & Co sold 722 Sarepta Therapeutics shares in Q4 2018, an estimated $117K.
Prentiss Smith & Co first reported a position in Sarepta Therapeutics in Q1 2016 and held it in 11 quarters.
Prentiss Smith & Co's Sarepta Therapeutics position peaked at $288K in Q1 2018.
336 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2018.

Based on Prentiss Smith & Co's 13F filing for Q4 2018, filed 15 Jan 2019.